Aquaporin (AQP) Q1 2025 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 TU earnings summary
6 Jun, 2025Financial performance and guidance
Q1 2025 revenue was DKK 3.2 million, down from DKK 6.2 million in Q1 2024, mainly from Forward Osmosis Market Development.
EBITDA (before special items) loss improved to DKK 15.3 million from DKK 19.3 million in Q1 2024, aligning with expectations.
Cash and cash equivalents stood at DKK 58.5 million as of March 31, 2025, up from DKK 2.0 million a year earlier.
Full-year 2025 guidance reaffirmed: revenue of DKK 60–80 million and EBITDA (before special items) loss of DKK 45–55 million.
Revenue is expected to be backend loaded, with most materializing in the second half of 2025.
Strategic and business developments
Strategic accounts focus led to repeat orders and diversified revenue streams.
Continued collaboration with Gallo achieved strong pilot-scale results in wine concentration.
Signed a strategic framework agreement in China to improve industrial wastewater treatment.
Expanded presence in South and Latin America with new orders for wastewater and well water projects.
Secured pilot contracts in Ireland and China, and completed a successful trial with Singapore's PUB.
Leadership and organizational updates
CEO Matt Boczkowski will step down for personal reasons, remaining until end of September 2025 at the latest.
Board of Directors has started the search for a new CEO.
Latest events from Aquaporin
- 44% revenue growth, improved margins, and 2024 outlook reaffirmed after capital raise.AQP
H1 202423 Jan 2026 - 2024 revenue fell 32% but Industrial Water surged 192%; rights issue and incentives below target.AQP
H2 202423 Dec 2025 - Revenue guidance cut after sharp H1 decline, with strategic review to secure future funding.AQP
H1 202523 Nov 2025 - Q3 revenue rose 14% year-on-year as capital-raising efforts intensify for future growth.AQP
Q3 2025 TU13 Nov 2025 - Order delays impacted Q3 revenue, but new partnerships and innovations support 2025 growth.AQP
Q3 2024 TU13 Jun 2025